Investigational drug · Phase 2
CRC01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "CRC01"
First trial start
2021
Mar 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CRC01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- High-grade B-cell Lymphoma
- Transformed Follicular Lymphoma (TFL)
- ALL (Acute B-Lymphoblastic Leukemia)
- Lupus Nephritis
- Lupus Nephritis (LN)
- SLE
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CRC01" as an intervention, largest first.
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT05464030 · 220 participants · Start Aug 4, 2022 · Primary completion Oct 23, 2026
Drug: M9140; M9140 and 4 more · For: Colorectal Cancer
Sites: Encinitas, California; Fresno, California; Providence, Rhode Island · 35 sites in all
Curocell Inc.Industry
NCT04836507 · 91 participants (planned) · Start Mar 2, 2021 · Primary completion Aug 15, 2030
Drug: CRC01; Fludarabine and 1 more · For: Relapsed Large B-cell Lymphoma; Refractory Large B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL) and 4 more
Sites: Seoul, South Korea · 2 sites in all
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT03384940 · 86 participants · Start Feb 23, 2018 · Primary completion Aug 9, 2019
Drug: DS-8201a · For: Colorectal Neoplasm
Sites: Duarte, California; Los Angeles, California; Santa Monica, California · 25 sites in all
- Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus ErythematosusNot yet recruiting
Curocell Inc.Industry
NCT07364396 · 39 participants (planned) · Start Feb 2026 · Primary completion Jun 2030
Drug: CRC01 · For: Lupus Nephritis; Lupus Nephritis (LN); SLE and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial.
Kim WS, Kim SJ, Yoon DH, et al. · Blood 2026
- Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Seo HJ, Yoo WH, Jung K, et al. · Cancer Res Treat 2026
- Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.
Siena S, Chalabi M, Goodwin R, et al. · Cancer Treat Rev 2026
- Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.
Spehner L, Bouard A, El Kaddissi A, et al. · Int J Cancer 2026
- Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study-The EMOGI-CRC01 Study.
Catani G, Kim S, Waisberg F, et al. · Cancers (Basel) 2025
- Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, et al. · Nat Commun 2025
Also in development for Relapsed Large B-cell Lymphoma
- TC011Phase 21 trial
TICAROS Co., Ltd. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.